Skip to main content

Advertisement

SpringerLink
Log in

Acute myocardial infarction and subacute stent thrombosis associated with cabazitaxel: a case report

  • Case Report
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Case Although newer cancer treatments and supportive care treatments have led to vast improvements in the management of complications associated with cancer treatment, sometimes they might cause serious side effects such as coronary artery disease, myocardial infarction and heart failure. These complications may occur any time during or after chemotherapeutics. In this report we present a patient with prostate cancer who experienced myocardial infarction and stent thrombosis probably caused by cabazitaxel -a new chemotherapeutic agent- administration. Conclusion Cardiologists and oncologists should take into consideration the cardiac side effects of new chemotherapeutic agents with the aim of maximizing both quality of life and survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–47.

    Article  PubMed  CAS  Google Scholar 

  2. Oudard S. TROPIC: phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol. 2011;7(4):497–506.

    Article  PubMed  CAS  Google Scholar 

  3. Geiger S, Lange V, Suhl P, Heinemann V, Stemmler HJ. Anticancer therapy induced cardiotoxicity: review of the literature. Anticancer Drugs. 2010;21(6):578–90.

    Article  PubMed  CAS  Google Scholar 

  4. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000;22(4):263–302.

    Article  PubMed  CAS  Google Scholar 

  5. Viale PH, Yamamoto DS. Cardiovascular toxicity associated with cancer treatment. Clin J Oncol Nurs. 2008;12(4):627–38.

    Article  PubMed  Google Scholar 

  6. Łacko A, Włodarska I, Zymliński R, Mazur G, Wróbel T, Gisterek I. Cardiac toxicity in cancer therapy. Pol Merkur Lekarski. 2002;13(73):79–85.

    PubMed  Google Scholar 

  7. Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev. 2011;37(4):300–11.

    Article  PubMed  CAS  Google Scholar 

  8. Vorinostat (Zolinza). Package insert. Whitehouse Station, NJ: Merck & Co. Inc. 2010.

  9. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695–704.

    Article  PubMed  CAS  Google Scholar 

  10. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.

    Article  PubMed  CAS  Google Scholar 

  11. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.

    Article  PubMed  CAS  Google Scholar 

  12. Villanueva C, Bazan F, Kim S, Demarchi M, Chaigneau L, Thiery-Vuillemin A, et al. Cabazitaxel: a novel microtubule inhibitor. Drugs. 2011;71(10):1251–8.

    Article  PubMed  CAS  Google Scholar 

  13. Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther. 2011;5:117–24.

    PubMed  CAS  Google Scholar 

  14. De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet. 2010;376(9747):1147–54.

    Article  PubMed  Google Scholar 

  15. De Bono JS, Sartor O. Cabazitaxel for castration-resistant prostate cancer—author’s reply. Lancet. 2011;377(9760):122–3.

    Article  Google Scholar 

  16. Dangas GD, Caixeta A, Mehran R, Parise H, Lansky AJ, Cristea E, et al. Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial Investigators. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation. 2011;123(16):1745–56.

    Article  PubMed  Google Scholar 

  17. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug events. Clin Pharmacol Ther. 1981;30(2):239–45.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We wish to thank the patient, his family members, and our co-workers for their contribution to this study.

Funding

All supports for this study came from institutional and departmental resources.

Conflicts of interest

The authors of this paper report no conflicts of interest. The authors confirm that they have permission to reproduce any copyrighted material.

Author information

Authors and Affiliations

  1. Department of Cardiology, Başkent University School of Medicine, Saray Mah, Yunusemre cad, No:1, 07400, Alanya, Antalya, Turkey

    Seher Gokay & Davran Cicek

  2. Department of Cardiology, Başkent University School of Medicine, Bahcelievler, No: 1, 07490, Ankara, Turkey

    Haldun Muderrisoglu

Authors
  1. Seher Gokay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Davran Cicek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Haldun Muderrisoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seher Gokay.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gokay, S., Cicek, D. & Muderrisoglu, H. Acute myocardial infarction and subacute stent thrombosis associated with cabazitaxel: a case report. Int J Clin Pharm 34, 418–421 (2012). https://doi.org/10.1007/s11096-012-9629-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-012-9629-z

Keywords

Search

Navigation